karuna deal

Quote








We're doomed as well. The Neurocrine dismal data doesn't bode well for us since were not that much more significantly better than them. There will be a reality check coming before Q-2 next year. Never should have left my previous gig.
 












Neurocrine, Abbvie and others will be following soon enough. This unique MOA will have a very short shelf life. BMS is acutely aware of the competition chasing on their heals. Recouping their 15 billion dollars anytime soon is unlikely. The goals will be a pipe dream to hit. I took the gig but realize I will be using it as a transition job at this point. Smart play I feel as the environment here will turn south quickly.
 




anonymous said:
Neurocrine, Abbvie and others will be following soon enough. This unique MOA will have a very short shelf life. BMS is acutely aware of the competition chasing on their heals. Recouping their 15 billion dollars anytime soon is unlikely. The goals will be a pipe dream to hit. I took the gig but realize I will be using it as a transition job at this point. Smart play I feel as the environment here will turn south quickly.
Click to expand...
Good to know our LT is asleep at the wheel! Loading our company with 15 billion in debt - yes that is a 1 and a 5 with a B - to purchase a product that is more or less dead on arrival.
 




anonymous said:
Good to know our LT is asleep at the wheel! Loading our company with 15 billion in debt - yes that is a 1 and a 5 with a B - to purchase a product that is more or less dead on arrival.
Click to expand...
Yep company financial advisors are fools on this and their heads should roll. No chance in hell they recoup this 15 billion dollar acquisition cost. They are playing us reps as fools on this. The ball will roll downhill and Smash the reps within 2 years on this horrific investment.
 




anonymous said:
Yep company financial advisors are fools on this and their heads should roll. No chance in hell they recoup this 15 billion dollar acquisition cost. They are playing us reps as fools on this. The ball will roll downhill and Smash the reps within 2 years on this horrific investment.
Click to expand...
The financial advisors are incentivized to rubber-stamp any deal. They don't get paid a fee for their services otherwise. The ELT and their subordinates should know better.

The worst aspect of this investment is that we don't have a way out if it doesn't pan out. They have overleveraged the company and bet the entire farm on this product. At least with the bad dealmaking of the past years we had profits coming in from other products that could compensate for the malinvestment. We are now sitting on knife's edge with Revlimid cash flows disappearing, and Eliquis and Opdivo soon to be gone in a couple years. There is no way out now. What a stupid, stupid investment that will put tens of thousands of jobs at risk.
 




anonymous said:
The financial advisors are incentivized to rubber-stamp any deal. They don't get paid a fee for their services otherwise. The ELT and their subordinates should know better.

The worst aspect of this investment is that we don't have a way out if it doesn't pan out. They have overleveraged the company and bet the entire farm on this product. At least with the bad dealmaking of the past years we had profits coming in from other products that could compensate for the malinvestment. We are now sitting on knife's edge with Revlimid cash flows disappearing, and Eliquis and Opdivo soon to be gone in a couple years. There is no way out now. What a stupid, stupid investment that will put tens of thousands of jobs at risk.
Click to expand...

most drug companies look to recoup their investment within 10 years of launch if not sooner..at 15 billion, karxt will never get out of the red. Even selling 1.25 billion per year will keep them in the red. its a pipe dream to think the drug will significantly surpass 1 billion in annual sales. The titanic will sink before reaching the Atlantic.
 




i am an investor and have been shorting BMY since it was trading in the 70's. the gift that keeps on giving. i will be holding on until it hits zero. the stock and company is a donut.
 




anonymous said:
most drug companies look to recoup their investment within 10 years of launch if not sooner..at 15 billion, karxt will never get out of the red. Even selling 1.25 billion per year will keep them in the red. its a pipe dream to think the drug will significantly surpass 1 billion in annual sales. The titanic will sink before reaching the Atlantic.
Click to expand...
Will be interesting to see what the year 1 goals will be. It’s a coach 22.
 




anonymous said:
most drug companies look to recoup their investment within 10 years of launch if not sooner..at 15 billion, karxt will never get out of the red. Even selling 1.25 billion per year will keep them in the red. its a pipe dream to think the drug will significantly surpass 1 billion in annual sales. The titanic will sink before reaching the Atlantic.
Click to expand...
What say it ain’t so. is this a dumpster fire even before the product gets approved?
 








anonymous said:
They’ll be a honeymoon period for 1st two quarters here before this place implodes. That’s assuming that the product receives approval.
Click to expand...
What is the pharmacy strategy for our drug access? I haven't heard of a plan and I hear this is the weakest area for BMS as a company. Who calls on specialty pharmacies?
 
























Top Bottom
Back
Quote